CSL Behring Overview
Company Headquarters: USA
Founded: 2000
Workforce: ~27,000
Revenue: USD 10.56 Billion (December 31, 2021)
Company Working: CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia; hereditary angioedema; inherited respiratory disease; and neurological disorders. CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. Company collaborates with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research. CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity, and superior performance. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries. CSL Limited is the parent company of global biotechnology leader CSL Behring; the world's largest collector of human plasma, CSL Plasma; and global leader in influenza prevention, Seqirus. CSL Limited is based in Melbourne, Victoria, Australia, and is traded on the Australian Securities Exchange (ASX) under the symbol CSL.
